NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/28/2024
Back to search
Official data from USPTO
ALMEE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
05/28/2024
Trademark type
Combined
Nice classes
9, 41, 42, 44
Filing date
10/24/2022
Registration date
05/28/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/28/2024
Last transaction
05/28/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
99
Owner location
Gothenburg, SE
Examiner
RILEY, KATHERINE
Law office
M80
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of of a green outline of overlapping, rounded geometric figures all connected at the bottom above "ALMEE" in stylized green font. The color white represents background, outlining, shading, and/or transparent areas and is not part of the mark.
Holders and representatives
Holders
Vicore Pharma AB
Representatives
Sarah J. Schneider SHERIDAN ROSS P.C.
Technical classification
Nice Classes
Class 9Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Downloadable computer software with medical information and content for facilitating the provision of medical advice in the field of depression and anxiety related to Pulmonary Fibrosis; downloadable computer software programs for the administration of scientific content in the nature of analysis of medical data; downloadable computer programsin particular interactive downloadable medical software for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis and for supporting medical personnel for the purpose of treating depression and anxiety; downloadable computer software program which is designed to assist patients in reducing and coping with the symptoms of depression and anxiety related to Pulmonary Fibrosis as well as in improving their wellbeing and social occupational functioning and to support health care professionals involved in the treatment of patients with depression and anxiety related to Pulmonary Fibrosis by facilitating the provision of medical advice; downloadable computer application software for websitesmobile telephones and mobile devicessoftware for treating patients suffering from depression and anxiety related to Pulmonary Fibrosis; downloadable printable educational materials featuring therapeutic medical and counselling contentin the nature of informationformsinstructionschartsstudiesdata and related coaching and advice in the field of depression and anxiety related to Pulmonary Fibrosistreatment of depression and anxiety related to Pulmonary Fibrosisrelated health and wellness; downloadable electronic publicationsnewsletters and articles for use by medical professionals and patients in the field of depression and anxiety related to Pulmonary Fibrosis
Class 41
Providing of on-line training and continuing education in the nature of virtual lectures in the field of medicinehealth and wellness for users in the medical fields with the aid of software; Educational servicesproviding continuing professional education courseswebinarsseminarsworkshops in the field of medicinehealth and wellness for patients suffering from depression and anxiety related to Pulmonary Fibrosis and for medical personnel specialized on the treatment of depression and anxiety
Class 42
Providing a website featuring digital therapeutic technology that enables users to access resources for treating depression and anxiety related to Pulmonary Fibrosis; providing an online digital therapeutic platform in the nature of providing on-line non-downloadable software for providing behavioural health servicescoachingcounsellingadvice in the field of depression and anxiety related to Pulmonary Fibrosis; conducting medical and scientific and technological research in the field of depression and anxiety related to Pulmonary Fibrosis; Scientific and technological servicesconducting technological research and design of digital therapeutics for computer-based interactive and online psychological intervention and counselling in the field of depression and anxiety related to Pulmonary Fibrosis; providing temporary use of non-downloadable computer programs for administration of digital therapeutic and medical content in the field of depression and anxiety related to Pulmonary Fibrosis and the treatment of depression and anxiety related to Pulmonary Fibrosis
Class 44
Therapeutic servicesmedical counsellingpsychological counsellingmedical advice and medical information provided to patients withcare givers treatingdepression and anxiety related to Pulmonary Fibrosis; Providing medical informationcomputer-based interactive medical support services in the nature of providing online medical advice for assisting with treatment of patients suffering from depression and anxiety related to Pulmonary Fibrosis and their families
Publications
History of USPTO decisions and trademark events.
35 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/28/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/12/2024
PUBO
PUBLISHED FOR OPPOSITION
03/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/21/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/21/2024
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
02/01/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
01/19/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/17/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/06/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/14/2023
GNRT
NON-FINAL ACTION E-MAILED
09/14/2023
CNRT
NON-FINAL ACTION WRITTEN
09/14/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/13/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/13/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/07/2023
GNRT
NON-FINAL ACTION E-MAILED
09/07/2023
CNRT
NON-FINAL ACTION WRITTEN
09/07/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
08/18/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/28/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/01/2023
GNSL
LETTER OF SUSPENSION E-MAILED
02/01/2023
CNSL
SUSPENSION LETTER WRITTEN
02/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/25/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/25/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/19/2023
GNRT
NON-FINAL ACTION E-MAILED
01/19/2023
CNRT
NON-FINAL ACTION WRITTEN
01/19/2023
DOCK
ASSIGNED TO EXAMINER
01/19/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/07/2022
NWAP
NEW APPLICATION ENTERED
10/27/2022
Continuous trademark protection
Get notified about every new filing that threatens ALMEE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.